Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Dual Biologic and JAK Inhibitor Combination Therapy for Severe Hidradenitis Suppurativa
Description
The talk addressed the challenge of treating severe hidradenitis suppurativa (HS) when monotherapy biologics lose effectiveness or only partially control disease. The speaker argued that for some patients with ongoing pain, flares, and poor quality of life, adding a second immunomodulator—such as a dual biologic regimen or a biologic plus a JAK inhibitor—may help move patients from partial improvement to meaningful functional control, rather than relying on repeated prednisone or multiple antibiotics. A case example illustrated stepwise escalation from infliximab and other therapies to combined biologic/JAK treatment, with better symptom control. The speaker reviewed emerging evidence, mostly from GI and rheumatology literature, suggesting low rates of serious adverse events with several combinations, while noting that some pairings, such as TNF plus IL-1, should be avoided because of infection risk. Survey data showed many HS specialists are already using dual-targeted therapy, most commonly TNF plus IL-17 or IL-17 plus JAK inhibitors. Practical advice included vaccine planning, lab monitoring, and documenting baseline disease activity before adding a second agent. The overall message was cautious optimism: dual therapy is not for routine use, but may be appropriate for selected severe HS patients while new studies and bispecific agents are being developed.
View moreConclusions
- Dual biologic or biologic plus small-molecule therapy may be a useful escalation strategy for severe hidradenitis suppurativa when monotherapy leaves patients only partially improved.
- The main goal of combination treatment is to move patients from partial response to meaningful functional improvement and better quality of life, rather than to use dual therapy routinely for all patients.
- Available evidence is still limited, but case reports, case series, and extrapolated GI/rheumatology data suggest that many biologic plus JAK inhibitor or biologic-plus-biologic combinations do not show major new safety signals.
- Among combination approaches, TNF plus IL-17 appears to be the most commonly used pairing in HS practice, largely because these are familiar and accessible drug classes.
- Safety data from other diseases suggest that serious adverse events with some dual-targeted regimens are uncommon, though caution is warranted because the evidence base is not robust.
- TNF plus IL-1 inhibition should generally be avoided because of prior evidence of increased serious infection risk in rheumatoid arthritis.
- Clinicians should plan vaccinations, monitor labs carefully, and document baseline disease activity before adding a second agent so the incremental benefit of combination therapy can be assessed.
- The presentation supports earlier and more effective initial treatment of HS so patients do not have to reach a point where dual therapy becomes necessary.
- Alayo et al. Crohn’s & Colitis. 2022.
- Alayo et al. Crohn’s & Colitis. 2022.
- Mease et al. Arthritis & Rheumatology. 2018.